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In vivo assessment of tumor glucose catabolism by positron emission tomography (PET) has become a highly valued study in the
medicalmanagementofcancer.Emergingtechnologiesoﬀerthepotentialtoevaluateinvivoanotheraspectofcancercarbohydrate
metabolism related to the increased anabolic use of monosaccharides like sialic acid (Sia). Sia is used for the synthesis of sialylated
oligosaccharides in the cell surface that in cancer cells are overexpressed and positively associated to malignancy and worse
prognosis because of their role in invasion and metastasis. This paper addresses the key points of the diﬀerent strategies that have
been developed to image Sia expression in vivo and the perspectives to translate it from the bench to the bedside where it would
oﬀer the clinician highly valued complementary information on cancer carbohydrate metabolism that is currently unavailable
in vivo.
1.Introduction
There is no doubt that in vivo imaging of glucose catabolism
by positron emission tomography (PET) through the use
of the PET tracer Fluorine-18-2-ﬂuoro-2-deoxy-D-glucose
(FDG) has revolutionized diagnosis and staging of cancer
[1]. FDG, an analogue of glucose, is transported into cells
by glucose transporters and follows the glycolytic pathway
being phosphorylated by hexokinase into FDG-6-phosphate.
At this point FDG is metabolically trapped because it cannot
follow the normal glycolytic pathway due to the substitution
of the 2  hydroxyl group by Fluorine 18 (18F), causing its
accumulation in the cell. Higher accumulation of FDG in
cancer cells compared to normal cells allows the imaging by
PET of the “Warburg eﬀect” or aerobic glycolysis which is
uniquelyobservedincancer[2].Theassociationofthiseﬀect
to malignancy has made FDG an indispensable or at least
a very important imaging agent in the diagnosis, staging,
restaging, and assessment of treatment in various types of
cancer including lung, colorectal, esophageal, stomach, head
and neck, thyroid, cervical, ovarian, and breast cancers, as
well as melanoma and most types of lymphoma [1, 3].
The in vivo imaging of anabolic rather than catabolic
carbohydrate pathways has a potential usefulness in cancer
management by oﬀering the clinician complementary infor-
mation on cancer carbohydrate metabolism that is currently
unavailable in vivo. This paper addresses the key points of
diﬀerent strategies that have been developed to image the
in vivo expression of sialylated oligosaccharides synthesized
by an essential cellular process known as glycosylation
[4]. Glycosylation involves the synthesis and attachment
to proteins (glycoproteins) and lipids (glycolipids) of a
structurally diverse group of oligosaccharides chains also
known as glycans that are synthesized in the endoplasmic
reticulum and Golgi apparatus of all human cells. Along this
paper the role of sialylated antigens in the glycophenotype
of cancer, their biosynthesis, and emerging imaging tools
are described in text and ﬁgures as the foundations of a
preliminary suggestion towards a new clinical approach in
tumor imaging.
Each type of human cell displays in its surface an array
of glycans attached to proteins or lipids to form glycocon-
jugates. The diﬀerent types of monosaccharides and linkage
combinations can be found on glycans code for biological2 International Journal of Molecular Imaging
information that translates into structural or functional
properties of the glycoconjugate. The type and degree of
expression of glycans is determined by the type and activities
of the proteins involved in their synthesis that can be
diﬀerent from one cell type to another and even diﬀer to
some extent between the same types of cell. This dynamic
temporospatial characteristic of glycosylation and the great
intrinsic information it can carry as a “glycan code” have
been evolutionarily selected as an important mechanism for
cells to communicate and enhance distinct physiologic and
pathologic states, including malignant transformation [5].
The “glycan code” has been probed and imaged exten-
sively in vitro mostly by the use of antibodies that recognize
carbohydrate epitopes or through carbohydrate-binding
proteins known as lectins [6]. In the case of cancer certain
characteristicsoftheglycancodehave beenclearlyassociated
to increased tumor aggressiveness and worse prognosis. One
of these being the overexpression of sialic acid (Sia) residues
that are present in many characterized carbohydrate antigens
[7].
2.SialylatedAntigensin
t h eGl y c o p h e n o typeo fCan c e r
A substantial component that distinguishes malignant
from benign glycophenotypes is the neoexpression or
overexpression of sialylated epitopes in the cell surface
that include sialyl-Tn (STn; Siaα2→6GalNAc-T/S), sia-
lyl T (ST; Siaα2-3Galβ1-3GalNAc-T/S), sialyl Lewis X
(SLex;S i a α2,3Galβ1,4(Fucα1,3)GlcNAc), and sialyl Lewis
A( S L e a/CA19-9; Sia2,3Galβ1,3(Fucα1,4)GlcNAc), Figure 1.
Additionally, various tumors including small cell and non-
small cell lung carcinomas, multiple myeloma, neuroblas-
toma, and Wilms’ tumor express Sia as a homopolymer
called polysialic acid or PSA (Siaα2,8Sia) [8–12]. The neo-
or overexpression of these sialylated antigens is mainly
caused by an increase in the expression of sialyltransferases
(STs) and fucosyltransferases (FUTs), glycosyltransferase
enzymes responsible for their synthesis that add Sia and
fucoseresiduestoglycans,respectively.Additionally,eﬀective
increase in antigen synthesis requires not only glycosyltrans-
ferase overexpression but also adequate donor and accep-
tor substrate synthesis which requires regulation of other
elements of the glycosylation machinery [13]. This increase
in sialylated antigen expression during cancer progression
has been associated to hypoxic conditions that develop in a
growing tumor and induce transcription of STs, FUTs, and
nucleotide-sugar transporters that provide them with donor
substrate [14–17].
Overexpression of sialylated antigens like SLea and SLex
plays an important role in the biology of cancer, particularly
the metastatic process. Overexpression of these antigens in
circulating cancer cells allows them to attach to a family
of endogenous lectins called selectins that are expressed
in endothelial cells of high endothelial venules (HEVs),
but also platelets and leukocytes [18]. Selectins normally
participate in the ﬁrst phase of what is known as the
leukocyte adhesion cascade that allows leukocytes to roll
over the inﬂamed vascular endothelium through selectin-
carbohydrate interactions mediated by ligands that express
SLex and SLea epitopes. Leukocyte rolling gives way to more
stable interactions with endothelial integrins that allow them
to transmigrate to the interstitial space to culminate an
immune response [18]. Cancer cells that disperse from a
primary tumor and access the vascular compartment have
exploited this leukocyte adhesion cascade mechanism to
attach to HEV and extravasate to initiate the establishment
of metastatic lesions. Also, overexpression of SLea/x antigens
has been found to facilitate tumor angiogenesis by mediating
cancer cell adhesion to endothelial cells [19, 20].
It is clear that increased expression of sialylated antigens
on cancer cells is closely implicated in the process of
cancer progression, and more malignant cancer cells tend
to have a more enhanced expression of these carbohydrate
determinants [19]. The numerous clinical statistics made
available to date show that the intensity of SLea/x and sialyl
Tn expression on cancer cells signiﬁcantly correlates with the
prognosis of patients and are reviewed elsewhere [21–24]. A
statistically signiﬁcant correlation between the postoperative
patient prognosis and SLea expression has been reported
for colon and stomach cancers while its correlation with
SLex expression has been reported for lung, breast, prostate,
stomach, colon, and urinary bladder cancers [25]. Also, in
both small cell and nonsmall cell lung carcinomas, colorectal
cancer, and multiple myeloma, the expression of PSA has
been correlated with tumor progression [8, 9, 11, 12, 26].
Unfortunately, the determination of the sialylation status,
particularly of solid tumors, is currently performed mainly
on tissue sections obtained from tumor biopsies limiting the
number of possible assessments through time.
3.SialicAcidandIts Biosynthesis
The name sialic acid collectively refers to a family of over
50 naturally occurring sugars and a growing number of
synthetic analogs. In humans the predominant Sia is N-
acetylneuraminic acid [27]. Sia is a nonulosonic amino sugar
with a carboxylate at the C1 position that is ionized at
physiological pH giving it a negative charge (Figure 2). Sia
has the potential for additional substitutions with acetyl,
methyl, sulphate, and phosphate groups at the hydroxyl
groups on the 4-, 7-, 8-, and 9-carbons that give it additional
properties. The negative charge of Sia and its terminal
position in glycans have given it a predominant role in
determining the nature of glycan interactions involved in
many essential functions of human physiology.
The biosynthesis of Sia begins in the cytosol with
the formation of N-acetylmannosamine (ManNAc) from a
relatively minor proportion of UDP-N-acetylglucosamine
(UDP-GlcNAc), obtained form the extracellular environ-
ment [28] or derived from GlcNAc via the action of
GlcNAc 2-epimerase [29]( Figure 2). In mammals, the
ManNAc is then phosphorylated to give ManNAc-6-
phosphate (ManNAc-6P). The second step involves the con-
densation of either ManNAc or MacNAc-6P with phospho-
enolpyruvate (PEP) to give neuraminic acid or neuraminicInternational Journal of Molecular Imaging 3
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Figure 1: Chemical structures of sialylated antigens associated to malignancy. Sialyl-Tn (Siaα2→6GalNAc-T/S), sialyl T (Siaα2-3Galβ1-
3GalNAc-T/S), sialyl Lewis X (SLex;S i a α2,3Galβ1,4(Fucα1,3)GlcNAc), and sialyl Lewis A (SLea;S i a α2,3Galβ1,3(Fucα1,4)GlcNAc).
acid-9P, respectively. In mammals, neuraminic acid-9P is
then dephosphorylated to generate neuraminic acid (Sia).
Finally, in the nucleus the activation of Sia with cytidine
monophosphate (CMP-Sia) is generated with the use of
cytosine triphosphate (CTP) [30]. Once in the cytosol CMP-
Sia is then transported to the Golgi lumen by a speciﬁc
transporter (CMP-SiaTr) where it is used as donor substrate
by more than twenty human sialyltransferases (STs) that
incorporate it into the nonreducing end of glycans [16, 31,
32].
Linkage of Sia by STs can be done to a terminal
galactose residue (Gal) via α2,6 or α2,3-linkage, to N-
acetyl-galactosamine(GalNAc)orgalactosamineresiduesvia
α2,6-linkage, or to another Sia as an α2,8 homopolymer
(Figure 3) .T h ep r e s e n c eo ra b s e n c eo fS i aa sw e l la st h et y p e
of linkage it presents in the glycan have been selected in
evolution as recognition characteristics that allow or hamper
biding of glycan ligands, thus determining important molec-
ular interactions that aﬀect cell behavior including cell-cell,
cell-matrix, and cell-soluble molecule interactions that play
roles in both physiological and pathological processes [7].
4.SialicAcidImaging In Vivo
Because of the clear association that has been established
between sialylated antigen overexpression and tumor aggres-
siveness, the imaging of tumor sialylation would oﬀer a
concomitant or alternative study to PET-FDG imaging not
only to diagnose cancer but also to assess patient’s prognosis.
To obtain the in vivo sialylation status of a tumor is a clinical
asset that must be translated from the bench to the bedside.
There are at least two strategies for the in vivo imaging of
tumor Sia expression. One involves metabolic labeling that
allows imaging of de novo synthesis of Sia, and the second
one involves native Sia recognition by imaging probes.
4.1. Metabolic Labeling. Metabolic labeling allows the study
of a metabolic pathway by administering to the cells com-
pounds that are modiﬁed analogs of natural substrates for
that particular pathway. Modiﬁcation of these compounds
aims at providing a means for their detection without
interfering with their metabolic use. An ideal candidate
compound for evaluating tumor sialylation in vivo has to
b ec e l lp e r m e a b l e ,h a st ob ea b l et oe n t e rt h eC M P - S i a
biosynthesis pathway at a committed stage, and although
modiﬁed has to be eﬃciently used by STs. The use of labelled
Sia or CMP-Sia is restricted because of the lack of plasma
membrane transporters and the negative charge of unmod-
iﬁed Sia that limits its cellular permeability. Uptake studies
with 18F-labelledsialicacidsN-acetyl-3-[18F]ﬂuorosialicacid
(3-Sia) and N-acetyl-2-deoxy-2,3-diﬂuorosialic acid (2,3-
diSia) showed ineﬃcient uptake and unsuitability for in vivo
imaging [33]. An alternative to solve this problem is the use
of modiﬁed permeable Sia analogs [34, 35]o rp e r m e a b l e
Sia precursors that can be subsequently detected by imaging
probes. Sia precursors, particularly based on ManNAc, have
been favored over Sia analogs for in vitro and in vivo imaging
because of lower cost and synthetic tractability of ManNAc
over Sia [36].
Of the diﬀerent analogue precursors of Sia biosynthe-
sis, ManNAc analogues are ideal candidates for metabolic
labeling because ManNAc is the ﬁrst pathway intermediate
to be committed to Sia biosynthesis, assuring that imaging of
the labelled ManNAc analog reﬂects glycan Sia expression.
And although ManNAc is permeable, ManNAc analogs
can be further acetylated to increase passive membrane
permeability [37].
Among many modiﬁcations that have been achieved
on the ManNAc sugar with chemical reporters [38] that
allow its detection, only an azide-labelled bioorthogonal
chemistry [39] has successfully been used to image in vivo its
incorporation as glycan-bound Sia [40]. The azide group at4 International Journal of Molecular Imaging
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that is ionized at physiological pH giving it a negative charge. Sia is synthesized in the cytosol and is activated in the form of CMP-Sia in
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theC2carbonofManNAcanalogsdoesnotinterferewiththe
ﬂux of the precursor towards Sia synthesis, activation in the
form of CMP-Sia or ST-mediated transfer. Also, it is abiotic
allowing the development of both intracellular and surface
chemoselective ligation strategies for its eﬃcient detection
bybioorthogonalchemistrythroughmodiﬁedphosphinesor
alkynes.
A peracetylated analogue of ManNAc bearing the azide
chemical reporter group (Ac4ManNAz) has been admin-
istered to mice in vivo without toxicity and was found
to be suitable for imaging [41, 42]. After cellular uptake
Ac4ManNAz is deacetylated in the cytoplasm and then
metabolicallyconvertedtoN-azidoacetylsialicacid(SiaNAz)
that is then activated with CMP and used by STs as donor
substrate to be incorporated into glycans ( Figure 4(a)). The
glycan-associated SiaNAz is then probed in vivo through the
“Staudinger ligation” that allows the azide group to interact
with triphenylphosphine derivatives [39]. An electrophilic
trapofmethylestergroupinorthopositiontothephosphine
structureprovidesareactivesiteforthenucleophilicnitrogen
from the azide group that temporarily forms an aza-ylide
intermediary (not stable in water) with the phosphorus
atom. Intramolecular cyclization between the nitrogen and
the carbonyl group of the methyl ester group releases
methanol and forms a stable amide bond rather than the
products of aza-ylide hydrolysis.
In vivo animal imaging potential of this strategy in a
murine model of lung carcinoma has been recently reported
[43]. Ac4ManNAz was pulsed in mice intraperitoneally for
7 days. After this labeling period the resulting SiaNAz
was detected by administration on day 11 of biotinylated
phosphines (Figure 4(b)) that were detected 2 hours after
by intravenous injections of ﬂuorescent or radionuclide-
labelled avidin molecules. Radionuclide detection withInternational Journal of Molecular Imaging 5
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a SPECT camera which is the most closely related to
what human applications would use was achieved with an
Indium-111-labelled Neutravidin-DOTA, showing a signiﬁ-
cant azido-labelled ManNAc-dependent increase in tumor-
to-tissue contrast. As the authors of this paper suggest, this
strategy requires further improvement by reducing it to
a one-step probe approach by using phosphine molecules
modiﬁed with gamma or positron emitting radioisotopes
and with an improved hydrophilic nature of phosphines to
reduce the nonspeciﬁc stromal binding that was observed in
this study. Also, other compounds like cyclooctynes could
be used to detect azide groups via strain-promoted azide-
alkyne cycloaddition (Figure 4(a))[ 44]. The cyclooctyne
molecule can be more easily modiﬁed to generate reactants
with enhanced kinetics. Some derivates possess a ring strain
andelectron-withdrawingﬂuorinesubstituentsthattogether
promote the [3 + 2] dipolar cycloaddition with azides
to form regioisomeric mixtures of triazoles. This reaction
has higher reaction kinetics compared to the Staudinger
ligation [38] and has been further improved by synthesizing
second-generation diﬂuorinated cyclooctynes (DIFOs) that
have propargylic ﬂuorine atoms that increase its interaction
energy with the azide (Figure 4(a))[ 45]. These DIFOs have
been successfully employed for dynamic in vivo imaging of
developingzebraﬁsh[41],andimportantadvanceshavebeen
made to improve their synthesis [46].
It is worth considering that ﬂuorophore modiﬁed phos-
phines or cyclooctynes could also be used for imaging of the
sialylation status of superﬁcial cancers like skin melanoma
or colorectal cancer through ﬂuorescent endoscopy. It is
noteworthy to mention that advances in positron emitters
through the Staudinger ligation have been achieved using
phosphine-substituted thioesters with 18F-ﬂuoroethylazide
[47].
4.2. Probes for Recognition of Native Sia. As e c o n ds t r a t e g y
consists in using imaging probes that recognize native Sia in
the cell surface. Historically, sialic acids have been explored
in vitro using plant lectins like wheat germ agglutinin
(WGA) that detects Sia independently of its type of linkage,
Sambucus nigra lectin (SNA) that recognizes α2,6 Sia or
Maackia amurensis aggluttinin (MAL) that recognizes α2,3
Sia. Also, antibodies directed against SLex or SLea deter-
minants have been used for many years; this is the case
of CA19-9 a tumoral marker used for detection of SLea
determinants in gastrointestinal tumors. These in vitro tools
have been diﬃcult to translate in vivo not only because
of their immunogenicity, that at least for antibodies could
be circumvented by humanizing them, but also because
of their molecular weight, that would restrict them to the
vascular compartment. This vascular restriction would not
be a problem if the aim was to image the expression of
Sia on the vascular network of a tumor, for example, or
in chronic inﬂammatory diseases. In the case of lectins,
immunogenicity could be avoided if human endogenous
sialic-acid-recognizing lectins were to be used like siglecs or
selectins,butagaintheirusewouldprobablybelimitedtothe
vascular compartment.
Nonetheless, other alternatives show promise mainly in
the ﬁeld of magnetic resonance imaging for the detection of
native Sia molecules (Figure 5). Frullano et al. reported the6 International Journal of Molecular Imaging
H2O
R = AC
RO
RO
RO
OH
OH
OH
OH
OH OH
OH
OH
OH
OH
OH OR
HN
HO
HO
HO
HO
HO
HO
HO
HO
HO
HO
HO
HO
HO
HO
N
N
N
H
N
H
N
N
N
N
N
N
N
H
N
H
N
H
N
H
N
H
CMP
COOH
ST
ST
AC4ManNAz
AC4ManNAz
Metabolism
Metabolism
SiaNAz
CO2H
CO2H
CO2H
CO2H
CO2H
Cyclooctyne
R
R
Probe
Probe
R
R
R
R
P:
OCH3
F
F
F
F
CO2H
R = probe −N2
Electrophilic trap
−CH3OH
Bioorthogonal chemistry
Staudinger ligation
O
O
O
O
O
O
O
O
O O
O
O
O
O
O
O
O
O O
O
O
R
O
O
O
O O
O
O
O
O
O
O
O
O
O
N3
N3
R = AC
RO
RO
RO
OR
HN
O
O
N3
OH OH
HO
HO
N
H
CMP
COOH
O
O
O
N3
N3 OH
OH
HO
HO
HO
N
H
CO2H
O O
O
N3
N3
Ph
Ph
Ph
Ph Ph
Ph
CO2H
OH OH CO2H
−
P
+
P
+
HO
HO
N
H
O
O
R
O
O
O O
Ph Ph
OH OH CO2H
P
OCH3
Amide bond
2+3 ycloaddition c
SiaNAz
SiaNAz
A a-ylide z
Phosp ine h
With ﬁrst generation cyclooctynes for in vivo use
With second generation (DIFO) for in vivo use cyclooctynes
-
-
N
H
(a)
Figure 4: Continued.International Journal of Molecular Imaging 7
O
O
O
O
O O
O
O
O
O
O
O
HN
HN
OH
OH
OH
OH
HO
HO
HO
HO
N
H
N
H
N
H
F
F
F
F
NH
O
3
S
Avidin
+
Avidin
+
4
O
O
HN
N
H
NH
O
O
O
O
3
S 4
O
O
HN
N
H
NH
O
3
S 4
N N
N
O O
O
N3
OH
OH
HO
HO
N
H
CO2Me
Ph2P
CO2H
H H
H H
H H
Biotin
R = R =
NH
NH
SiaNAz
Phosp ine h
R NH
Ph2P
CO2
−
CO2
−
Cyclooct ne i
Detection of biotin- hosphine and biotin-diﬂuorinated with labelled avidine cyclooctynes p
(b)
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used for SiaNAz detection in vivo in animal models of lung cancer, a similar strategy could be employed using cyclooctynes.
synthesisoftwolanthanideionligandsdenominatedL1(3,9-
Bis{6-[(4,5-dihydroimidazol-2-yl)aminoethyl]-10-[2-(dihy-
droxyboranylphenyl)]-2-oxo-3,6,9-triazadecyl}-6-carbox-
ymethyl-,6,9-triazaundecanedioic Acid) and L2 (3,9-
Bis[3-(dihydroxyboranylphenyl)-2-oxo-3,6-diazaheptyl]-6-
carboxymethyl-3,6,9-triazaundecanedioic acid). These com-
pounds were obtained by inclusion of a central chelating
unit based on the DTPA-bisamide structure (DTPA, diethyl-
enetriamine pentaacetic acid). Molecular modeling studies
indicate that both compounds can allow two-site binding to
Sia through ester formation by interaction of the boronate
function in the ligand with the geminal diol of Sia and
an electrostatic interaction between a positively charged
aminoimidazolium (L1) or aminomethyl (L2) group present
in metaposition relative to the boronic function and
the carboxylate group of Sia [48]. Both gadolinium
complexed ligands showed high speciﬁc and reversible
binding towards Sia. The dynamic equilibrium that the
compounds showed between their sialic-acid-bound and
free states would allow them to be excreted physiologically.
Similarly, a thiourea-based synthetic receptor (2-{[3-(4-
Nitrophenyl)ureido]methyl}phenylboronic acid) reported
by Regueiro-Figueroa et al. that contains phenylboronic acid
functions also showed a high speciﬁcity towards Sia due
to cooperative binding through ester formation with the
phenylboronicacidandhydrogenbondinteractions between
the carboxylate group and the thiourea moiety (Figure 5)
[49].
This native recognition approach compared to metabolic
labelling has the potential to recognize the type of Sia
linkages and even carbohydrate antigens, oﬀering additional
speciﬁc information, but this aim requires further research.8 International Journal of Molecular Imaging
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Figure 5: Receptors for native recognition of Sia. The carboxylate and diol groups of sialic acid have been exploited for
recognition purposes by lanthanide ligand DTPA-bisamide compounds L1 (3,9-Bis{6-[(4,5-dihydroimidazol-2-yl)aminoethyl]-10-[2-
(dihydroxyboranylphenyl)]-2-oxo-3,6,9-triazadecyl}-6-carboxymethyl-,6,9-triazaundecanedioic acid) and L2 (3,9-Bis[3-(dihydroxyboran-
ylphenyl)-2-oxo-3,6-diazaheptyl]-6-carboxymethyl-3,6,9-triazaundecanedioic acid) bearing boronic and functional groups (L1: aminoim-
idazolium and L2: aminomethyl). Also, a thiourea-based synthetic receptor (2-{[3-(4-Nitrophenyl)ureido]methyl}phenylboronic acid) has
been reported to show a high speciﬁcity towards Sia.
5. Conclusions
Although glycans equip the cell surface with eﬃcient and
dynamic signalling mechanisms that have been partially
decipheredtoconveyimportantclinicalinformation,glycans
and glycan-mediated interactions have been rarely targeted
for in vivo imaging with some exceptions that particularly
involve quantiﬁcation of liver function [50–52].
In vivo imaging of tumor sialylation is in the transition
stage from the bench to the bedside and is only limited by
minor improvements in radioisotope probe synthesis to be
used concomitantly or alternatively with FDG in the medicalInternational Journal of Molecular Imaging 9
management of cancer. The metabolic labelling with Sia
precursor analogs and detection oﬀered by bioorthogonal
chemistry oﬀer at this moment a high value for clinical use
in the near future. It is important to press for the continuing
technological development of these strategies to assess as
soon as possible their clinical value in diagnosis, staging,
prognosis, and treatment response. Imaging of tumor sia-
lylation brings together information of both catabolic and
anabolic processes associated to malignancy which can only
improve patient management.
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